Clinical Trial Update: Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 trial evaluating neoadjuvant ipilimumab in patients with urothelial carcinoma undergoing surgical resection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Urothelial Carcinoma | Phase 1 | Status: COMPLETED